Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Karakterisering van on-target bijwerkingen van TRK-remmers
nov 2020 | Longoncologie, Maag-darm-leveroncologie